CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analyst consensus is “Moderate Buy”: Seven of nine analysts rate CAMP4 Therapeutics a buy, with an average 12-month price target of $9.56 versus the stock’s recent $4.41 price.
• Recent earnings missed expectations: The company reported a quarterly loss of $0.58 per share, well below the $0.24 loss analysts expected, on revenue of $1.78 million.
• Insider activity was mixed: A director sold 400,000 shares, while the CFO bought 10,000 shares; overall, insiders sold substantially more shares than they purchased during the latest quarter.

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $9.5625.

Several equities research analysts have recently commented on the stock. Weiss Ratings lowered shares of CAMP4 Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $5.00 to $9.00 in a research report on Tuesday, June 16th. Zacks Research raised shares of CAMP4 Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, August 17th. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the stock a "buy" rating in a report on Wednesday, June 10th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th.

CAMP4 Therapeutics Stock Down 1.8%

Shares of CAMP4 Therapeutics stock opened at $4.41 on Friday. The company has a market cap of $276.73 million, a price-to-earnings ratio of -1.90 and a beta of 0.27. The company's 50 day moving average is $4.13 and its 200 day moving average is $4.35. CAMP4 Therapeutics has a twelve month low of $1.46 and a twelve month high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.The firm had revenue of $1.78 million during the quarter. Sell-side analysts expect that CAMP4 Therapeutics will post -0.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Andrew Schwab sold 400,000 shares of the company's stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the sale, the director directly owned 2,033,270 shares of the company's stock, valued at $8,214,410.80. This represents a 16.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kelly Gold bought 10,000 shares of the stock in a transaction dated Monday, August 31st. The shares were purchased at an average price of $3.96 per share, with a total value of $39,600.00. Following the completion of the transaction, the chief financial officer directly owned 10,000 shares in the company, valued at approximately $39,600. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have bought 46,031 shares of company stock valued at $99,051 and have sold 593,613 shares valued at $2,504,037. Corporate insiders own 21.69% of the company's stock.

Institutional Trading of CAMP4 Therapeutics

Large investors have recently made changes to their positions in the business. Bank of America Corp DE bought a new position in shares of CAMP4 Therapeutics in the 2nd quarter valued at about $78,000. Trails Edge Capital Partners LP bought a new stake in shares of CAMP4 Therapeutics in the 2nd quarter valued at approximately $8,446,935. Jupiter Topco LLC purchased a new position in shares of CAMP4 Therapeutics in the 2nd quarter worth approximately $27,581,000. 5AM Venture Management LLC purchased a new position in shares of CAMP4 Therapeutics in the 2nd quarter worth approximately $25,647,928. Finally, BlackRock Inc. bought a new position in shares of CAMP4 Therapeutics during the 2nd quarter valued at approximately $7,185,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source